Loading...
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
Hess, G Dreyling, M Oberic, L Gine, E Zinzani, PL Linton, Kim Vilmar, A Jerkeman, M Chen, JMH Ohler, A
Hess, G
Dreyling, M
Oberic, L
Gine, E
Zinzani, PL
Linton, Kim
Vilmar, A
Jerkeman, M
Chen, JMH
Ohler, A
Citations
Altmetric:
Abstract
The SCHOLAR-2 retrospective study highlighted poor overall survival (OS) with standard of care (SOC) regimens among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who failed a covalent Bruton tyrosine kinase inhibitor (BTKi). In the ZUMA-2 single-arm trial, brexucabtagene autoleucel (brexu-cel; autologous anti-CD19 CAR T-cell therapy) demonstrated high rates of durable responses in patients with R/R MCL who had previous BTKi exposure. Here, we compared OS in ZUMA-2 and SCHOLAR-2 using three different methods which adjusted for imbalances in prognostic factors between populations: inverse probability weighting (IPW), regression adjustment (RA), and doubly robust (DR). Brexu-cel was associated with improved OS compared to SOC across all unadjusted and adjusted comparisons. Hazard ratios (95% confidence intervals) were 0.38 (0.23, 0.61) for IPW, 0.45 (0.28, 0.74) for RA, and 0.37 (0.23, 0.59) for DR. These results suggest a substantial survival benefit with brexu-cel versus SOC in patients with R/R MCL after BTKi exposure.
Description
Date
2023
Publisher
Collections
Files
Keywords
Type
Article
Citation
Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton K, et al. Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma. LEUKEMIA & LYMPHOMA. 2023 2023 OCT 14. PubMed PMID: WOS:001086585900001. English.